Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.39 |
| ▸ | CA2 | P00918 | 6/20 | 0.39 |
| ▸ | CA9 | Q16790 | 6/20 | 0.39 |
| ▸ | CA5A | P35218 | 3/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 5/20 | 0.37 |
| ▸ | CA12 | O43570 | 4/20 | 0.37 |
| ▸ | CA3 | P07451 | 4/20 | 0.37 |
| ▸ | CA6 | P23280 | 4/20 | 0.37 |
| ▸ | CA7 | P43166 | 4/20 | 0.37 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13284094 | 0.93 | ACLY (0.36) | CA1CA2CA9CA5APABPC1 | |
| SCHEMBL10281398 | 0.84 | ALDH1A1 (0.51) | CA1CA2CA9CA5APABPC1 | |
| SCHEMBL11640624 | 0.84 | TUBB4A (0.34) | PABPC1EIF4HACLYALDH1A1KDM4E | |
| SCHEMBL11540286 | 0.83 | PABPC1 (0.36) | PABPC1EIF4HACLYALDH1A1KDM4E | |
| SCHEMBL11543053 | 0.80 | ALDH1A1 (0.56) | CA1CA2CA9CA5AACLY | |
| SCHEMBL11549637 | 0.80 | KDM4E (0.50) | CA1CA2CA9CA5APABPC1 | |
| SCHEMBL16577895 | 0.79 | PABPC1 (0.38) | PABPC1EIF4HALDH1A1KDM4EHPGD | |
| SCHEMBL11546060 | 0.78 | L3MBTL1 (0.43) | CA1CA2CA9CA5ACA4 | |
| SCHEMBL11543213 | 0.76 | ALDH1A1 (0.57) | CA1CA2CA9CA5AACLY | |
| SCHEMBL2883320 | 0.75 | MAPT (0.49) | CA1CA2CA9CA5ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2017-08-31 | — | — | US | disclosed |
| US-9682928-B2 | Bumetanide analogs, compositions and methods of use | NEUROPRO THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS INC. | 2015-03-19 | — | — | US | disclosed |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-4161531-A | Diuretic and saluretic 5-sulfamoylbenzoic acid derivatives carrying a heterocyclic substituent | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-07-17 | — | — | US | disclosed |
| US-4118397-A | DIURETICS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-10-03 | — | — | US | disclosed |
| US-4111953-A | DIURETICS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-09-05 | — | — | US | disclosed |
| US-4093735-A | DIURETICS | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-06-06 | — | — | US | disclosed |
| US-4010273-A | DIURETICS, SALURETICS | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CA1 1022/4885CA2 471/4885CA9 710/4885 |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | ABCG2, ABCB1, TRPV1 | CA1 1755/4885CA2 1572/4885CA9 1396/4885 |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CA1 1762/4885CA2 1422/4885CA9 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.